{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:00:20Z","timestamp":1772791220600,"version":"3.50.1"},"reference-count":42,"publisher":"Informa Healthcare","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2016,6,2]]},"DOI":"10.3111\/13696998.2016.1149482","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T22:13:48Z","timestamp":1454969628000},"page":"604-610","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness analysis of febuxostat in patients with gout in Spain"],"prefix":"10.3111","volume":"19","author":[{"given":"F.","family":"Perez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"D\u00edaz-Torn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Carcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"CIT0002","volume-title":"Clinical practice guidelines for management of gout","author":"Spanish Society of Rheumatology (SER).","year":"2013"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2004.01.001"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200205000-00015"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.03.043"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80158-3"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800885"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.10.004"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000209435.89720.7c"},{"key":"CIT0010","volume-title":"Epidemiolog\u00eda de las enfermedades reum\u00e1ticas. Manual SER de las enfermedades reum\u00e1ticas","author":"Carmona L.","year":"2004","edition":"4"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182314d40"},{"key":"CIT0012","unstructured":"National Institute for Health and Clinical Excellence (NICE). Final appraisal determination. Febuxostat for the management of hyperuricaemia in people with gout. NICE, 2008. London (UK). https:\/\/www.nice.org.uk\/guidance\/ta164. Accessed April 20, 2015"},{"key":"CIT0013","unstructured":"Scottish Medicines Consortium (SMC). Febuxostat 80\u2009mg and 120\u2009mg Tablets (Adenuric) SMC No. 637\/10. 2010. Glasgow (UK). http:\/\/www.scottishmedicines.org.uk\/files\/advice\/febuxostat-Adenuric-FINAL-August-2010.pdf. Accessed April 20, 2015"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0617-1"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2009.07.011"},{"key":"CIT0018","volume-title":"Gu\u00eda y recomendaciones para la realizaci\u00f3n y presentaci\u00f3n de evaluaciones econ\u00f3micas y an\u00e1lisis de impacto presupuestario de medicamentos en el \u00e1mbito del CatSalut. Generalitat de Catalunya","author":"Puig-Junoy J","year":"2014"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202421"},{"issue":"10","key":"CIT0020","first-page":"704","volume":"60","author":"Becker MA","year":"2009","journal-title":"Arthritis Rheum"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken457"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080814"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269"},{"key":"CIT0024","first-page":"2429","volume":"31","author":"Borstad GC","year":"2004","journal-title":"J Rheumatol"},{"key":"CIT0025","unstructured":"Institute of Medical Science World Publications Ltd. A health economic assessment of febuxostat in the management of gout. Data on File. Version No. 1.0. 2007. London (UK)"},{"key":"CIT0026","unstructured":"General Council of the Association of Official Pharmacists. General Council of the Association of Official Pharmacists Database: Bot PLUS 2.0. Madrid (Spain). https:\/\/botplusweb.portalfarma.com\/. Accessed April 22, 2015"},{"key":"CIT0027","unstructured":"Royal Decree-Law 8\/2010. Extraordinary measures to reduce the public deficit. Amended by the Royal Decree-Law 9\/2011. Madrid (Spain). http:\/\/www.boe.es\/boe\/dias\/2010\/05\/24\/pdfs\/BOE-A-2010-8228.pdf. Accessed April 2015"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2012.06.014"},{"key":"CIT0029","volume-title":"Healthcare cost database eSALUD [Internet]","author":"Gisbert R","year":"2015"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200017050-00006"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/S0213-9111(02)71933-X"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X112606"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-117"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem150"},{"key":"CIT0035","unstructured":"Ipsen UK. Febuxostat for the treatment of gout: single technology appraisal submission to the National Institute for Health and Clinical Excellence. 2008. London (UK). http:\/\/www.nice.org.uk\/guidance\/ta164\/documents\/manufacturer-ipsen-submission2. Accessed January 2015"},{"key":"CIT0036","unstructured":"Redding L, Hornberger J, Cowens W, et\u00a0al. Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada. Poster presented at: Canadian Agency for Drugs and Technologies in Health Symposium; April 3-5, 2011; Vancouver, British Columbia, Canada. https:\/\/www.cadth.ca\/poster-presentations-0. Accessed April 2015"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2011-100065"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0227"},{"issue":"4","key":"CIT0039","first-page":"S52","volume":"20","author":"Smolen LJ","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.2.165"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq346"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140679"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.3111\/13696998.2016.1149482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T21:50:28Z","timestamp":1481752228000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.3111\/13696998.2016.1149482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,3,2]]},"published-print":{"date-parts":[[2016,6,2]]}},"alternative-id":["10.3111\/13696998.2016.1149482"],"URL":"https:\/\/doi.org\/10.3111\/13696998.2016.1149482","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}